#USA #Boston #Colorectal Cancer #TTX-MC138 #TransCode Therapeutics

TransCode Therapeutics Unveils Phase 2a Clinical Trial for TTX-MC138

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the clinical stage biotechnology firm that is at the forefront of immuno-oncology and RNA therapies, has announced the launch of its Phase 2a clinical trial to evaluate TTX-MC138. This groundbreaking therapeutic candidate is aimed at patients diagnosed with colorectal cancer who are ctDNA-positive after undergoing curative-intent therapies. This phase of investigation showcases the company's commitment to advancing innovative treatment options for high-risk cancer patients.

The trial, conducted in partnership with Quantum Leap Healthcare Collaborative (QLHC), a significant player in cancer research, will recruit up to 45 patients who have completed standard treatment but show signs of minimal residual disease indicated by circulating tumor DNA (ctDNA). The presence of ctDNA suggests that while patients may not display radiographic signs of disease, there may still be underlying cancerous cells that could lead to recurrence.

Leading the research efforts are Principal Investigators Dr. Emil Lou from the University of Minnesota and Dr. Zhaohui Jin from the Mayo Clinic Comprehensive Cancer Center, with oversight from Dr. Paula Pohlmann of the MD Anderson Cancer Center. These esteemed professionals are at the vanguard of cancer treatment, and their involvement underscores the trial's importance.

The relevance of ctDNA testing has garnered increased attention in oncology, with its potential to provide a sensitive, real-time assessment of residual disease. TransCode believes that combining ctDNA testing with TTX-MC138 could pave the way for enhanced therapeutic interventions earlier in the treatment process. The trial aims to uncover vital data about how TTX-MC138 could reduce the chances of cancer recurrence in high-risk patients.

TTX-MC138 is designed to inhibit microRNA-10b (miR-10b), a microRNA implicated in cancer metastasis. TransCode's initial Phase 1a clinical trial confirmed its safety and established a recommended dose for further testing. This early promise fuels excitement about TTX-MC138's potential effectiveness.

The forthcoming trial not only strives to gather data on TTX-MC138's biological efficacy but also aims to enhance understanding of the ctDNA-guided strategies. These findings are expected to contribute to the growing body of evidence that supports the use of advanced testing techniques in managing colorectal cancer.

By leveraging existing clinical sites involved in QLHC's PRE-I-SPY platform trial, the current investigation aims to expedite patient enrollment and data collection. Many participating centers are recognized members of the National Comprehensive Cancer Network (NCCN), ensuring that patients receive the highest standard of care throughout the study.

In conclusion, the commencement of this Phase 2a clinical trial marks a significant milestone for TransCode Therapeutics as they push forward innovative strategies to combat colorectal cancer. As the study unfolds, the company anticipates contributing to the evolving landscape of cancer treatment, providing hope for effective therapies that target minimal residual disease early on. The outcome of this trial could redefine therapeutic approaches for patients facing the challenging journey of colorectal cancer treatment.